<DOC>
	<DOCNO>NCT01056614</DOCNO>
	<brief_summary>This phase II trial study side effect well give fludarabine phosphate , busulfan , anti-thymocyte globulin follow donor peripheral blood stem cell transplant , tacrolimus , methotrexate work treat patient myeloid malignancy . Giving chemotherapy , fludarabine phosphate busulfan , donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving anti-thymocyte globulin transplant tacrolimus methotrexate transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Phosphate , Busulfan , Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant , Tacrolimus , Methotrexate Treating Patients With Myeloid Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Determine incidence severity acute graft-versus-host disease ( GvHD ) . SECONDARY OBJECTIVES : I . Determine pharmacokinetics intravenous ( IV ) busulfan include interdose variability evaluation limit sample strategy . II . Determine thymoglobulin ( anti-thymocyte globulin ) pharmacokinetics . III . Determine incidence donor engraftment . IV . Determine system toxicity &gt; = grade 3 per Common Terminology Criteria Adverse Events ( CTCAE ) version ( v. ) 3 . V. Determine incidence severity chronic GvHD . VI . Determine incidence non-relapse mortality day +100 1 year ( yr ) . VII . Determine incidence relapse . VIII . Determine relapse-free survival . IX . Determine incidence Epstein-Barr virus ( EBV ) activation . OUTLINE : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute day -9 -6 , busulfan IV 3 hour day -5 -2 , anti-thymocyte globulin IV 6 hour day -3 -2 4 hour day -1 . Patients undergo allogeneic peripheral blood stem cell ( PBSC ) transplant day 0 . Patients receive tacrolimus IV continuously orally ( PO ) every 12 hour begin day -1 taper day 180 methotrexate IV day 1 , 3 , 6 , 11 . After completion study treatment , patient follow 1 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Chronic myelogenous leukemia chronic phase , accelerate phase treat blast phase ( CP2 ) Acute myeloid leukemia ( AML ) remission early relapse ( &lt; 10 % marrow blast ) Myelodysplastic syndrome ( MDS ) ( risk group ) Other myeloproliferative disorder DONOR : relate unrelated donor match human leukocyte antigen ( HLA ) A , B , C , DRB1 , DQB1 define high resolution deoxyribonucleic acid ( DNA ) type mismatch single HLAA , B , C , DRB1 DQB1 allele DONOR : donor must consent peripheral blood stem cell ( PBSC ) mobilization granulocyte colonystimulating factor ( GCSF ) leukapheresis ; relate donor collect Fred Hutchinson Cancer Research Center ( FHCRC ) , unrelated donor collect National Marrow Donor Program ( NMDP ) donor center DONOR : Age 1275 yr Cardiac insufficiency require treatment symptomatic coronary artery disease Hepatic disease , aspartate aminotransferase ( AST ) &gt; 2 time normal Severe hypoxemia , oxygen partial pressure ( pO2 ) &lt; 70 mm Hg , decrease diffusion capacity carbon monoxide ( DLCO ) &lt; 70 % predict ; mild hypoxemia , pO2 &lt; 80 mm Hg severely decrease DLCO &lt; 60 % predict Impaired renal function ( creatinine &gt; 2 time normal estimated creatinine clearance &lt; 60 ml/min ) MALE : ( [ 140 age year ] x ideal body weight [ kg ] ) /72 x serum creatinine ( SCr ) ( mg/dL ) FEMALE : .85 x ( [ 140age year ] x ideal body weight [ kg ] ) /72 x SCr ( mg/dL ) Human immunodeficiency virus ( HIV ) positive patient due risk reactivation acceleration HIV replication Female patient pregnant breast feed Life expectancy severely limited disease malignancy DONOR : donor reason unable tolerate mobilization leukapheresis procedure DONOR : donor HIVpositive , hepatitis B C antigenpositive DONOR : female donor positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>